A Clinical Validation Study of a Computerized Movement Analysis of the Colonoscope

April 13, 2019 updated by: Andreas Slot Vilmann, Rigshospitalet, Denmark

A Clinical Validation Study of Two Computerized Systems Called the 3D-Colonoscopy Progression Score and 3D-Colonoscopy Retraction Score

Colonoscopy is the considered gold standard for diagnosing diseases in the colon. A colonoscopy is normally divided into the insertion from anus to cecum, the technical difficult part, and a retraction or diagnostic part. No objective measure exists to evaluate the performance of a colonoscopy. Based on a movement analysis of the colonoscope we wish to seek evidence for an automated and objective system able to differentiate between endoscopists with various experience in a clinical setting. The movement analysis is based on information's from the colonoscope. Electromagnetic coils are built in along the length of colonoscopes. They generate a pulsed magnetic field that is picked up a receiver coil. The data-points for each coil are inserted into an algorithm for the movement analyzing. This analysis is done as a change between the tip of the scope, and the next tracked magnetic coil. The result is a relative movement of the colonoscope in relation to the previous position.

The study is conducted a three different University Hospitals in Denmark. Twenty physicians with experience in colonoscopy are voluntary included. Patients appointed to a screening colonoscopy are included and a minimum of five consecutive colonoscopies are recorded for each physician. We predict the system to be automated and objective tool correlated with the physician's technical level of expertise in clinical colonoscopy.

Study Overview

Detailed Description

Objectives:

  1. Gather validity evidence for the 3D-Colonoscopy Progression score (3D-CoPS) and 3D-Colonoscopy Retraction Score (3D-CoRS) in a clinical setting.
  2. Investigate the relationship between 3D-CoPS/3D-CoRS and a retrospective calculated Adenoma Detection Rate (ADR) of endoscopists with various experience.

Background:

Colonoscopy is the gold standard for diagnosing adenomas and colorectal cancer. High Adenoma Detection Rate (ADR) is essential to reduce the risk of subsequent colorectal cancer .To maximize the detection of adenomas during a colonoscopy the endoscopist need to see as much mucosa as possible. To increase the mucosa visualized quality indicators, such as bowel preparatin, cecal intubation rate and an average time of at least 6 minutes spent during withdrawal, should be used as supportive measures to minimize missed lesions and thereby decreasing interval cancer. Bowel preparation, cecal intubation and time spent during withdrawal are prerequisite measures for optimal visualization of the mucosa in the colorectum, but are not a quality measure for actual detected pathology. Time as a quality assurance for detection of adenomas means nothing if the physician isn't careful during withdrawal and look behind folds and change position to get a clear view of the mucosa surface. The ADR has been introduced as a surrogate measure of adequate visualization of the mucosa, but a recommend and a minimum number of 500 colonoscopies are needed to calculate a statistic reliable ADR. Although ADR is one of the most widely used and accepted quality indicators great variance in number of performed procedures and ADR among physicians exits, which makes ADR difficult to use in practice. Currently there is no quality parameter evaluating the individual procedure and to our knowledge no objective tools exits to help increase diagnostic accuracy during a colonoscopy. Objective, easy implementable and automatic measures are needed to ensure a high detection of adenomas and subsequently prevent missed lesions and interval cancers.

In collaboration with the Technical University of Denmark we have developed a score of progression and retraction during a colonoscopy, called 3D-Colonoscopy Progression Score (3D-CoPS) and 3D-Colonoscopy Retraction Score (3D-CoRS). We predict the systems to be automated and objective tool correlated with the endoscopists technical level of expertise in clinical colonoscopy.

Method and materials:

Retrospective study part:

The study is conducted at three different university hospitals. Twenty endoscopists with a lifetime experience of no less than 50 screening colonoscopies are voluntarily enrolled. To calculate the ADR for each endoscopist data of the last screenings colonoscopies is retrospectively collected (minimum 50 colonoscopies per endoscopist).

The following will be noted for each endoscopist:

  • Number of total colonoscopies
  • Number of colonoscopies within the last year
  • Number of other endoscopies
  • Number of screenings colonoscopies
  • Intern, junior resident, senior resident, consultant
  • Surgical or medical gastrointestinal background
  • Sex
  • Age
  • Time since graduation

Prospective part:

A minimum of five consecutive screenings colonoscopies for each endoscopist are included. Patients appointed to a screening colonoscopy are chosen due to a higher ADR (approximately 50%) and a more homogeneous group. All procedures are performed with a standard Olympus colonoscope model in combination with the Magnetic Endoscopy Imaging system (MEI). Data collection starts at the intubation of the colonoscope in the anus and stops when the procedure is finished. The data collection is fully automated without any interference from the investigators during the normal clinical setup.

Approval is applied at the Danish Data Protection Agency, the Danish Patient Safety Authority and the Regional Committee on Health Research Ethics.

General mathematical formulation for 3D-CoPS and 3D-CoRS:

Electromagnetic coils are built in along the length of the Olympus colonoscopes. They generate a pulsed low-intensity magnetic field that is picked up a receiver coil. The data-points for each coil are inserted into an algorithm for movement analyzing. The two main measurements conducted in relation with the colonoscopy is the Colonoscopy Progression Score (CoPS) and Colonoscopy Retraction Score (CoRS). Both of these have a joint basis for the analysis, in the form of a movement analysis. This analysis is done as a vector product between the tip of the scope, and the next tracked magnetic coil - where on the relative magnitude of the change in position is multiplied on. This results in a relative movement that is scaled with how much the scope moves in relation to the previous position, and how much this movement is deflected according to the direction the tip points in. This movement analysis is used for distinction between the progression- and retraction phase, which is essential, such that the CoPS and CoRS measurements is performed at the right times.

3D-CoPS: To perform the CoPS measurement, the above definition helps by defining the progression phase. The general belief is that if the scope progresses smoothly, the colonoscopist is experienced, and vice versa. Therefor tracking how much time the tip of the scope is "stagnant", is used to define the CoPS. Specifically, a two dimensional histogram is used, spanned across the movement area of the colonoscopy. Filling the histogram is simply performed by sampling the tip position at each time step, and putting it into the respective bin. If the scope is then stagnant at many stages throughout the procedure, the bins values will be locally very high. On the other hand, if a smooth progression is present, the bin values will be smoothly distributed, across all the different bins. This is the basis for the CoPS value. Finally followed with a normalizing, and scaling of the 2D histogram value, for easing interpretation.

3D-CoRS: Analyzing the retraction phase, must be done differently, as the tip is supposed to be stagnant, at different times, through this phase. Therefor the movement analysis, as described above, is used to measure how the instrument moves. This movement is then high-passed filtered, as experienced colonoscopist seems to have much more high frequency movements, where-in the novices moves with much lower frequency (more hesitant). This overall movement is evaluated as a difference between the different positions (by differentiation), and a count of peaks and valleys is done with a fitting margin. This final count is then high if an expert is performing the procedure, as more high frequency movements will take place, and low if a novice is performing the procedure.

Patient related information:

  • Number of polyps
  • The polyp size
  • Polyp type
  • Polyp histology
  • Polyp location

Validity:

Evidence of validity is based on Messicks five major sources (10).

Content:

1. 3D-CoPS and 3D-CoRS are being developed based on the evidence of an ongoing simulation-based validation study " A Validation Study of a Computerized Movement Analysis of the Colonoscope in Simulated Colonoscopy" and general good practice of how a colonoscope is withdrawn from cecum to anus.

Response process:

The process is standardized using an Olympus colonoscope and MEI system. All participants will be instructed informed of the systems and the data-collection. All data-collection regarding are presented in a uniform file-format. The 3D-CoPS and 3D-CoRS are objective, automated and unbiased tools.

Internal structure:

To ensure internal consistency of the 3D-CoPS and 3D-CoRS among the endoscopists a minimum of 5 consecutive colonoscopies are needed (based on an article not yet published). The score system is automated and unbiased why the internal structure in this regard is consistent.

Relationship to other variables:

We assume the sample data reflects a population that follows a probability distribution based on a fixed set of parameters. The correlation between experience (logarithmic) and scores will be investigated using Pearson's r. Scores from 3D-CoPS and 3D-CoRS will be correlated with patient and endoscopist variables. The endoscopist is not blinded during data-collection, which might affect the performance. Even thou data collection is fully automated, the technic during withdrawal of the colonoscope from caecum to anus could change and increase mucosa visualized and therefore polyp detection (increased awareness of the endoscopist).

Consequences:

Contrasting groups' method will be used to set a pass/fail standard based on the scores imitating aminimum performance during intubation, a minimum ADR and false positive and false negative will be investigated.

Ethics:

The study contains no biomedical involvement. Participants and patients will not suffer from any physical or psychological discomfort. All endoscopists will be provided with oral and written information and sign a letter of informed consent before entering the study. The collected data are anonymized.

Study Type

Observational

Enrollment (Actual)

9

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Copenhagen, Denmark, 2100
        • Copenhagen Acedemy of Medical Education and Simulation

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Colorectal cancer screening in Denmark involves citizens in the age from 50 to 74, who is invited to volunteerly participate in screening for bowel cancer. In the course of four years (2014-2017) every person in the age group will get an invitationto the screening program. From 2018 and onwards people aged 50-74 will be invited every second year. All participants take the hemocult test and if the test is positive they will be appointed to a screening colonoscopy.

Description

Inclusion Criteria:

  • Physicians or nurses with a lfetime experience of more than 50 screenings colonoscopies.
  • Patients appointed to a screenings colonoscopy according to the danish screening program for colorectal cancer.

Exclusion Criteria:

  • None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
3D-Colonoscopy Progression Score
Time Frame: 8 months
The score is based on a movement analysis of the colonoscope from anus until max insertion(cecum). It is scaled from 0-1000 .A score of zero equals an incomplete procedure and a score of 1 is a very poor score but the cecum was reached. Increasing score represents better technical performance with a maximum score of 1000.
8 months
3D-Colonoscopy Retraction Score
Time Frame: 8 months
The score is based on a movement analysis of the colonoscope from cecum to the anus. It is scaled from 0-1000. A score of zero equals a very poor score, Increasing score represents better technical performance with a maximum score of 1000
8 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Lars Konge, Prof, CAMES-Rigshospitalet

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

July 12, 2018

Primary Completion (ACTUAL)

January 20, 2019

Study Completion (ACTUAL)

February 20, 2019

Study Registration Dates

First Submitted

July 3, 2018

First Submitted That Met QC Criteria

July 3, 2018

First Posted (ACTUAL)

July 16, 2018

Study Record Updates

Last Update Posted (ACTUAL)

April 16, 2019

Last Update Submitted That Met QC Criteria

April 13, 2019

Last Verified

April 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • Clinical 3D-CoPS and 3D-CoRS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Colonoscopy

Clinical Trials on 3D-Colonoscopy Progression Score

3
Subscribe